EUVIMEDEUVIMED entdecken
LeserbriefMetaanalyse

Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer

Kadri Altundag

European Journal of Clinical Pharmacology · 2026-04 · 82 (4)

DOI: 10.1007/s00228-026-04037-3 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 30.03.2026. Verfasst von Kadri Altundag. Beteiligte Einrichtung: MKA Breast Cancer Clinic, Tepe Prime, Cankaya, Ankara, 06800, Turkey. altundag66@yahoo.com. Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • MKA Breast Cancer Clinic, Tepe Prime, Cankaya, Ankara, 06800, Turkey. altundag66@yahoo.com.

Zitieren

APA

Altundag, K. (2026). Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer. European Journal of Clinical Pharmacology, 82(4). https://doi.org/10.1007/s00228-026-04037-3

Vancouver

Altundag K. Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer. European Journal of Clinical Pharmacology. 2026;82(4). doi:10.1007/s00228-026-04037-3

BibTeX
@article{Altundag2026,
  author = {Altundag, Kadri},
  title = {Methodological considerations in sacituzumab govitecan meta-analysis for metastatic triple-negative breast cancer},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {4},
  doi = {10.1007/s00228-026-04037-3}
}
Kostenlos starten →